Serum Multiomics Profiling of Infertile Women Stratified by Etiology Reveals Distinct Metabolic, Lipidomic, and Exposomic Signatures
Journal of Proteome Research · 06.11.2026 · 25 (11) · 6179-6193
DOI: 10.1021/acs.jproteome.6c00545 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Proteome Research, online erschienen am 24.10.2026. Verfasst von Wenfeng Pan und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Laboratory, Guangdong Provincial Key Laboratory of Major Obstetric Diseases, Guangdong Provincial Clinical Research Center for…. Hauptthemen laut MEDLINE: Infertility, Female, Lipidomics. Die Arbeit nennt 31 Literaturangaben. Gefördert von: Guangdong Medical Research Foundation.
Abstract (Originalsprache)
Female infertility is evaluated primarily by hormonal assays and anatomical imaging, and its molecular landscape remains largely uncharacterized. We enrolled 247 women of reproductive age: 57 nonpregnant controls (NP), 59 women with normal pregnancies (Preg), and 131 infertile patients stratified into polyendocrine metabolic ovarian syndrome-related (PMOS, n = 49), organic/anatomical/inflammatory (OAII, n = 26), other endocrine/autoimmune (OEAI, n = 8), and unexplained (UEI, n = 48) infertility. Fasting serum underwent untargeted metabolomic, lipidomic, and exposomic profiling; classifiers were built with nested cross-validation and integrated via DIABLO, and exposure mixtures were assessed by BKMR. The integrated classifier separated PMOS (AUC 0.892) and UEI (AUC 0.993) from NP, whereas OAII was less separable (AUC 0.729, permutation p = 0.14); lipidomics alone outperformed the integrated model for PMOS and OAII (both DeLong p < 0.001). PMOS was marked by long-chain lipid upregulation, OAII by pan-lipidomic upregulation, and UEI by global lipid downregulation; etiology-stratified sensitivity analyses indicated that OAII heterogeneity diluted, rather than drove, its pooled signal. The pregnant reference group showed coordinate lipidomic and metabolomic remodeling that opposed the infertile acylcarnitine signature. Octabenzone (PIP > 0.98) and propylparaben (PIP 0.75–1.00) emerged as key exposures. Lipidomics emerged as the most informative layer, supporting precision molecular phenotyping of female infertility.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Clinical Laboratory, Guangdong Provincial Key Laboratory of Major Obstetric Diseases, Guangdong Provincial Clinical Research Center for Obstetrics and Gynecology, The Third Affiliated Hospital, Guangzhou M…
- Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Guangdong-Hong Kong Joint Laboratory for RNA Medicine, Medical Research Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen Universi…
- Department of Clinical Laboratory, Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou510655, China.
- Clinical Medicine Innovation Center, Shenzhen Hospital, Southern Medical University, Shenzhen518101, China.
ORCID-Profile: Wenfeng Pan
Förderung
- Guangdong Medical Research Foundation
Zitieren
APA
Pan, W., Wang, L., Cen, M., Cai, Z., & Wu, L. (2026). Serum Multiomics Profiling of Infertile Women Stratified by Etiology Reveals Distinct Metabolic, Lipidomic, and Exposomic Signatures. Journal of Proteome Research, 25(11), 6179-6193. https://doi.org/10.1021/acs.jproteome.6c00545
Vancouver
Pan W, Wang L, Cen M, Cai Z, Wu L. Serum Multiomics Profiling of Infertile Women Stratified by Etiology Reveals Distinct Metabolic, Lipidomic, and Exposomic Signatures. Journal of Proteome Research. 2026;25(11):6179-6193. doi:10.1021/acs.jproteome.6c00545
BibTeX
@article{Pan2026,
author = {Pan, Wenfeng and Wang, Linlin and Cen, Meifeng and Cai, Zhiliang and Wu, Long},
title = {Serum Multiomics Profiling of Infertile Women Stratified by Etiology Reveals Distinct Metabolic, Lipidomic, and Exposomic Signatures},
journal = {Journal of Proteome Research},
year = {2026},
volume = {25},
number = {11},
pages = {6179--6193},
doi = {10.1021/acs.jproteome.6c00545}
}
EUVIMED